Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines.

Literature DB >> 8485814

Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines.

J Robert¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1993 PMID： 8485814 DOI： 10.1007/bf00685610

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

× No keyword cloud information.

25 in total

1. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.

Authors: L Gianni; L Viganò; A Surbone; D Ballinari; P Casali; C Tarella; J M Collins; G Bonadonna
Journal: J Natl Cancer Inst Date: 1990-03-21 Impact factor: 13.506

2. High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.

Authors: W Greene; D Huffman; P H Wiernik; S Schimpff; R Benjamin; N Bachur
Journal: Cancer Date: 1972-12 Impact factor: 6.860

Review 3. Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration?

Authors: J Robert
Journal: Cancer Drug Deliv Date: 1987

Review 4. Pharmacodynamics in cancer therapy.

Authors: M J Ratain; R L Schilsky; B A Conley; M J Egorin
Journal: J Clin Oncol Date: 1990-10 Impact factor: 44.544

5. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

Authors: B Schott; J Robert
Journal: Biochem Pharmacol Date: 1989-11-15 Impact factor: 5.858

6. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.

Authors: J Robert; J P Armand; S Huet; M Klink-Alakl; G Recondo; P Hurteloup
Journal: J Clin Oncol Date: 1992-07 Impact factor: 44.544

7. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin.

Authors: S P Ackland; M J Ratain; N J Vogelzang; K E Choi; M Ruane; J A Sinkule
Journal: Clin Pharmacol Ther Date: 1989-04 Impact factor: 6.875

8. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities.

Authors: P Canal; J Robert; M Ramon; R Baurain; P Tresca; M de Forni; M Marty; E Pujade-Lauraine; R Bugat; A Magis
Journal: Clin Pharmacol Ther Date: 1992-03 Impact factor: 6.875

Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines.

1. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.

2. High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.

Review 3. Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration?

Review 4. Pharmacodynamics in cancer therapy.

5. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

6. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.

7. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin.

8. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities.

9. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.

10. A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients.

Review 1. Limited-sampling models for anticancer agents.

Review 2. Pharmacokinetic drug interactions with anticancer drugs.

Review 3. Clinical pharmacokinetics of epirubicin.